Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer drug trial halted early: what we know

NCT ID NCT02712905

Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called INCB059872 in people with advanced solid tumors or blood cancers that had not responded to standard treatments. The goal was to find a safe dose and see if it could control the disease. The trial was stopped early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

116 people

The number who actually took part.

Started

May 2016

Finished

Apr 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female subjects, age 18 years or older. * Presence of measurable disease that has been confirmed by histology or cytology. * Must not be a candidate for potentially curative therapy or standard-of-care approved therapy * Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2. Exclusion Criteria: * Receipt of anticancer medications, anticancer therapies, or investigational drugs within the defined interval before the first administration of study drug. * Any unresolved toxicity ≥ Grade 2 from previous anticancer therapy except for stable chronic toxicities (≤ Grade 2) not expected to resolve. * Laboratory and medical history parameters outside Protocol-defined range. * Known additional malignancy that is progressing or requires active treatment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ewing sarcoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia Ewing sarcoma hematopoietic and lymphoid system neoplasm myelodysplastic syndrome Myelodysplastic Syndromes myelofibrosis neuroendocrine carcinoma primary myelofibrosis small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Solid tumors and hematologic malignancy

Contacts and locations

Locations

  • Columbia University

    New York, New York, 10027, United States

  • Erasmus MC

    Rotterdam, Netherlands

  • Institut Jules Bordet

    Brussels, Belgium

  • Moores UCSD Cancer Center

    La Jolla, California, 92093, United States

  • Netherland Cancer Institute

    Amsterdam, Netherlands

  • Northwestern University

    Chicago, Illinois, 60208, United States

  • Oregon Health Science University

    Portland, Oregon, 97297, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

  • UCLA Medical Center

    Los Angeles, California, 90095, United States

  • University of Alabama

    Birmingham, Alabama, 35487, United States

  • University of Kansas Center for Research, Inc.

    Kansas City, Kansas, 66045, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • VU Medical Center

    Amsterdam, Netherlands

  • Vanderbilt University

    Nashville, Tennessee, 37240, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.